Micro Therapeutics Fills Out Aneurysm Pipeline With Dendron Embolic Coils
This article was originally published in The Gray Sheet
Executive Summary
Micro Therapeutics, Inc. expects to obtain 510(k) clearance for Dendron GmbH's line of neurovascular embolic coils for brain aneurysms by mid-2003
You may also be interested in...
MTI consolidation
Micro Therapeutics shutters operations in Bochum, Germany Dec. 30 to bring manufacturing and R&D functions to its headquarters in Irvine, Calif. MTI gained the Bochum facility in a $40 mil. purchase of Dendron (1"The Gray Sheet" Sept. 9, 2002, p. 13). MTI will terminate 60 employees, although key R&D personnel likely will move to Irvine...
MTI consolidation
Micro Therapeutics shutters operations in Bochum, Germany Dec. 30 to bring manufacturing and R&D functions to its headquarters in Irvine, Calif. MTI gained the Bochum facility in a $40 mil. purchase of Dendron (1"The Gray Sheet" Sept. 9, 2002, p. 13). MTI will terminate 60 employees, although key R&D personnel likely will move to Irvine...
MTI Onyx V. Aneurysm Coil Trial Protocol Revisited; PMA On Track For 2004
Micro Therapeutics' revised inclusion criteria for its U.S. pivotal trial comparing the Onyx LES liquid embolic system with Boston Scientific's GDC Ultrasoft coil to treat brain aneurysms will delay PMA filing by three fiscal quarters, MTI estimates